Moleculin Biotech (MBRX)
NASDAQ:MBRX
MBRX Stock Chart & Stats
$2.43
-$0.01(-0.56%)
At close: 4:00 PM EST
$2.43
-$0.01(-0.56%)
Day’s Range― - ―
52-Week Range$1.79 - $28.60
Previous CloseN/A
Volume63.82K
Average Volume (3M)2.74M
Market Cap
$12.97M
Enterprise Value-$5.57M
Total Cash (Recent Filing)$8.88M
Total Debt (Recent Filing)$359.00K
Price to Earnings (P/E)―
Beta1.62
Next Earnings
May 07, 2026EPS Estimate
-1.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.61
Shares Outstanding5,336,350
10 Day Avg. Volume1,958,319
30 Day Avg. Volume2,738,732
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market Cap-0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit94.39
Enterprise Value/Ebitda0.22
Forecast
1Y Price Target
$21.00Price Target Upside764.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-6.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical MilestoneA planned unblinded interim efficacy and safety readout tied to an enrollment milestone could confirm the preliminary remission signal and act as a major catalyst for the stock.
High-risk Patient ActivityDemonstrated activity in patients who failed venetoclax suggests potential benefit in a hard-to-treat population, reducing development risk and enhancing the drug's clinical value.
Safety ProfileObserved absence of cardiotoxicity strengthens Annamycin's safety profile relative to traditional anthracyclines and could enable use in earlier lines of AML.
Bears Say
Competitive LandscapeA crowded AML treatment field with several advancing competitors could limit market attention and make commercial uptake harder even if trial results are positive.
Data UncertaintyBlinded preliminary data require an unblinded interim analysis and formal data lock to confirm treatment assignment and true efficacy, leaving definitive conclusions uncertain.
Financing RiskReported operating losses and a modest cash position increase the likelihood of additional financing needs that could dilute existing shareholders.
Moleculin Biotech News
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $1.79 and its highest was $28.60 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $12.97M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is May 07, 2026 which is in 40 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Mar 19, 2026. The company reported $2.61 earnings per share for the quarter, beating the consensus estimate of -$6.113 by $8.723.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -1.66.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 5,336,350 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of $2.61 in its last earnings report, beating expectations of -$6.113. Following the earnings report the stock price went down -0.962%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
MBRX Stock 12 Month Forecast
Average Price Target
$21.00
▲(764.20% Upside)
Technical Analysis
Ownership Overview
22.30% Insiders
0.19% Mutual Funds
<0.01% Other Institutional Investors
77.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---